AMENDMENTS TO THE CLAIMS:

Please amend claims 1, 30, 31 and 58; and cancel claims 24, 26, 57 and 59 without prejudice or disclaimer. This listing of claims replaces all prior versions, and listings of claims in the application.

LISTING OF CLAIMS:

1.- 14. Cancelled.

15. (Currently Amended) A method for treating a mammalian subject for serum-associated hypergastrinemia, comprising:

(a) identifying a subject with serum-associated hypergastrinemia, but no consequent disease; and

(b) administering to said subject an immunogenic composition comprising a G17 peptide of sequence pyro-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu (SEQ ID NO: 1) or fragment thereof to thereby lower gastrin hormone levels to treat the hypergastrinemia, wherein administration of the composition is commenced prior to development of a consequent disease.

16.- 17. Cancelled.

18. (Original) The method according to claim 15, wherein the serum gastrin levels of said subject are reduced or maintained at a normal level.

19. (Original) The method according to claim 18, wherein the serum gastrin levels of said subject are reduced or maintained at less than 240 pg/mL.

20. (Original) The method according to claim 18, wherein the serum gastrin levels of said subject are reduced or maintained at less than 40 pg/mL.

21. (Previously Presented) The method of claim 18, wherein ~~said~~ gastric acid production is inhibited.

22. (Previously Presented) The method of claim 15, wherein the subject has pernicious anemia, a gastric tumor, or a gastric cancer consequent to the hypergastrinemia.

23. (Previously Presented) The method of claim 15, wherein the subject has cancer selected from the group consisting of colon cancer, stomach cancer, pancreatic cancer, esophageal cancer, and liver cancer consequent to the hypergastrinemia.

24.-26. (Cancelled)

27. (Previously Presented) The method of claim 15, wherein said immunogenic composition comprises said G17 peptide conjugated to an immunogenic carrier in a pharmaceutically acceptable carrier.

28. (Original) The method according to claim 15, wherein said G17 peptide fragment is linked by an amino acid spacer to an immunogenic carrier.

29. (Original) The method according to claim 28, wherein said carrier is selected from the group consisting of diphtheria toxoid, tetanus toxoid, and keylimpet hemocyanin.

30. (Currently Amended) The method of claim 58, wherein ~~said~~ the agent is a blocker ~~is~~ selected from the group consisting of ranitidine, cimetidine, fomatidine, and nizatidine.

31. (Currently Amended) The method of claim 58, wherein ~~said~~ the agent is a proton pump inhibitor ~~is~~ selected from the group consisting of omeprazole, lansoprazole, and patoprazole.

32. (Previously Presented) The method of claim 58, wherein said subject is administered said immunogenic composition before said agent.

33.-57. Cancelled.

58. (Currently Amended) ~~The method of claim 15,~~ A method for treating a mammalian subject to reduce agent-induced side-effects, comprising:

administering to the subject, who is being treated with or has been treated with~~also administering~~ an agent selected from ~~among~~ a histamine receptor blocker and a proton pump inhibitor, an immunogenic composition containing a G17 peptide of sequence pyro-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu (SEQ ID NO: 1) or a fragment thereof, whereby agent-induced gastrointestinal side-effects are inhibited.

59. Cancelled.